Supriya Lifescience’s Ambernath facility receives WHO GMP certification
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated